Patrick C. Lee patrick.lee.wg10@wharton.upenn.edu


University of Pennsylvania, Philadelphia, PA B.S.E., Magna Cum Laude, Bioengineering, 2001 M.S.E., Bioengineering, 2001


Adam L. Lessler


adam.lessler.wg10@wharton.upenn.edu Amherst College, Amherst, MA B.A., Summa Cum Laude, Phi Beta Kappa, Economics, 2001


University of Pennsylvania, School of Medicine, Philadelphia, PA M.D. Candidate, 2010


Wendy S. Liu


wendy.liu.wg10@wharton.upenn.edu Columbia College, New York, NY B.A., History, 1999


An opportunity in marketing or business development at a biotech/medical device company or life science start-up.


ev3, Plymouth, MN


Commercial Marketing Associate, Summer 2009


Developed 2010 commercial strategy plan for stents and atherectomy product lines. Conducted assessment of competitive landscape in self expanding stents and recommended product improvements. Evaluated market opportunity for thrombectomy product.


Quaker BioVentures, Philadelphia, PA Associate/Analyst, 2004-2008


Identified and evaluated life science investment opportunities at $700M venture capital fund. Executed 8 Quaker-led investments totaling $52M and 6 follow-on investments totaling $25M. Conducted industry research, financial modeling, technical and management diligence. Served as board observer on several portfolio companies. Managed investor report- ing and diligence requests during fundraising of Quaker BioVentures II.


Easton Associates, New York, NY Associate Consultant/Research Associate, 2002-2004


Completed 11 engagements including market opportunity assessments and commercialization strategies. Conducted primary research by identifying and interviewing physicians, key opinion leaders, payors and industry experts. Forecasted revenues for products tar- geted at cardiology, oncology, ortho- pedic, and rheumatology specialties.


An opportunity to use my clinical and business expertise to improve health care quality and delivery.


McKinsey and Company, Philadelphia, PA Summer Associate, Summer 2009 Evaluated strategic options to assist pharmaceutical benefits manager extract value from pharmaceutical companies. Developed baseline model to project prescription volume and profitability for drugs in 7 categories. Created and analyzed survey of primary care physicians to assess degree of differentiation of drugs in 20 different categories.


University of Pennsylvania Health System, Philadelphia, PA Summer Intern, Summer 2006


Researched and developed education- al materials to teach new UPHS house staff about pharmaceutical industry relationships. Conducted systematic review of literature on cost-effective- ness analyses for pharmaceutical agent aprotinin as part of hospital formulary recommendation made to Pharmacy & Therapeutics Committee.


Harvard Medical School, Boston, MA Research Assistant, Department of Health Care Policy, 2004-2005 Analyzed effects of financial incentives and hospital characteristics on cost and quality of care, leading to publi- cation of 3 manuscripts in peer- reviewed journals. Collaborated with physicians, economists, statisticians and other research professionals on multiple project teams.


Goldman, Sachs & Company, New York, NY


Analyst, Investment Banking Division, 2001-2002


Summer Analyst, Investment Banking Division, Summer 2000


An opportunity to evaluate and identify attractive healthcare companies to execute investment or M&A transactions.


Cowen Healthcare Royalty Partners, Stamford, CT


MBA Intern, Summer 2009


Evaluated royalty-based, revenue interest-based and structured financing investment transactions for healthcare private equity fund with over $500M in assets under management. Conducted industry, scientific, and financial diligence; developed invest- ment memos; created financial models for valuation and deal structuring.


PeriCor Therapeutics, Inc., New York, NY Senior Director, Corporate Development & Planning, 2005-2008


Member of team that closed licensing agreement with Schering-Plough on Phase III product. Managed business development operations. Contributed to strategic planning and participated in negotiations of term sheets, confi- dentiality and consulting agreements. Aided in clinical development planning and endpoint identification for regulatory approval.


J.P. Morgan Securities, New York, NY Associate Equity Research Analyst, Small/Mid-Cap Biotechnology, 2004-2005 Authored reports, updates and coverage initiations. Built financial models. Conducted physician interviews and clinical data analyses.


Deutsche Bank Securities, New York, NY Associate Equity Research Analyst, US Biotechnology, 2003-2004


Conducted detailed research and valuation of U.S. Biotechnology sector.


Natexis Bleichroeder, New York, NY Research Associate (Pharmaceuticals), Analyst (Biotechnology) 2000-2003


17


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40